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tent Thrombosis
he Effect of Intention on Perception*
ouglass A. Morrison, MD, PHD
akima, Washington
ince the presentation of meta-analyses by Camenzind et al.
1), Nordmain et al. (2), and the BASKET-LATE (Basel
tent Kosten Effeckivitats Trial–Late Thrombotic Events
rial) study and registry (3) at the European Society of
ardiology (ESC) meeting in 2006 (popularly known as the
ESC firestorm”), the world has been increasingly aware of
he potential for late stent thrombosis (LST [30 days to 1
ear]) or very late stent thrombosis (VLST [1 year]) with
rug-eluting stent (DES) implantation, and the possibility
hat said entity can present as an acute myocardial infarction
4,5). In the interest of sober reflection, it may be useful to
riefly reconsider the history leading up to and from that
entinel event (the ESC, not LST or VLST).
See page 1936
When balloon angioplasty (percutaneous transluminal
oronary angiography) was in its infancy (late 1970s and
980s), it was applied to 5% of ischemic patients, with
xpected success rates of 60% to 65%. Success was a 50%
ngiographic residual. Acute occlusive syndromes led to
5% emergency coronary artery bypass graft (CABG)
rocedures, and surgical standby was universal. Early repeat
rips to the laboratory occurred in 5% to 10% of cases; and
estenosis over the first 6 months occurred in upward of
ne-third of cases (6).
Bare-metal stents (BMS) did not (as is often implied
rom the simplistic reading of randomized trials) simply lead
o the reduction of restenosis from approximately one-third
o one-fourth or one-fifth of cases (depending upon patient
election and technique, among other factors). The BMS
rovided a means of treating most acute occlusive syn-
romes (dissection flaps, spasm, and recoil), virtually elim-
nating emergency CABG and surgical standby (accord-
ngly, to say stents have never been shown to reduce
ortality is analogous to arguing that parachutes have never
een demonstrated to reduce mortality for sky divers). The
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thec
merican College of Cardiology.
From the Yakima Heart Center, Yakima, Washington.MS also provided major improvement in acute success
20% vs.50% residual) quickly (decreased X-ray dye and
-ray exposure), allowed for more aggressive lesion anatomy
election (broadening the scope of percutaneous coronary
ntervention), and reduced restenosis (7).
However, BMS were initially associated with stent
hrombosis of 3% to 10%, until operators learned of the
enefits of high-pressure inflation, intravascular ultrasound
ontrol, and dual-antiplatelet therapy (meaning, aspirin plus
hienopyridine, especially as opposed to the use of dextran
nd coumadin) (7–11).
Since the ESC firestorm, the Swedish media’s reference
o “ticking time bombs” in patient’s chests, and cardiac
urgeons’ claims that 6,500 preventable deaths per year
ould be attributed to application of percutaneous coronary
ntervention to patients who should receive CABG, 2,200
reventable deaths per year derived from LST, and $7
illion per year being spent in 2006 on thienopyridines
dual-antiplatelet therapy) “whose only rationale was the
revention of an iatrogenic disease” (LST), the world first
earned of the subtle differences between patient based
eta-analyses and -regression (from published mean data).
t turned out that the available evidence did not support an
ncrease in long-term mortality from the use of DES rather
han BMS (12–14).
Additionally, clinicians began to recognize acute infarc-
ions in patient with LST, from BMS implantation (15).
ome actually recalled treating acute infarctions in patients
ith both early and late occlusion of bypass grafts.
Others came to recognize that in addition to cessation of
rescribed antiplatelet agents, and the “usual anatomic, and
linical suspects” (long lesions, small vessels, inadequate
cute results, diabetes mellitus), patient behaviors such as
ontinued tobacco use or cocaine use or failure to comply
ith statins seemed to pop up among patients needing a
ate-night treatment for LST (16).
In this issue of the Journal, Lee et al. (17), operators from
high-volume center in South Korea, reported 30 cases of
ery late (1 year) stent thrombosis that accumulated over
5-year period, and all presented as acute myocardial
nfarctions (17). This important complication occurred with
oth BMS (7 cases) and DES (23 cases). Unfortunately, we
re not given the denominators of patients treated during
his period with BMS or DES, or potential selection biases
nd/or methodological differences, which might allow any
eaningful comparison of the rates. The accompanying
ntravascular ultrasound data support mechanistic differ-
nces; specifically, late stent malapposition only occurred
mong the 23 cases of DES-associated VLST, not the 7
ases associated with BMS (17).
Limitations of this study derive from the fact that it is a
etrospective registry; as such, it is subject to potential
election biases, information biases, and confounding (18).
dditionally, it comes from a single, albeit large and busy,enter. It is possible to set up prospective registries with
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Stent Thrombosis May 4, 2010:1943–4re-defined patient selection and well-defined outcomes,
nd the Food and Drug Administration has “encouraged”
uch registry development as part of the conditions for
pproval of new DES. Alternatively, some form of long-
erm registry is the only practical means of assessing a
elatively infrequent complication. In other words, the
dvantages of reduction/elimination of the impact of known
nd unknown confounders, which derive from a well-done
andomized allocation, is not practical for the kinds of
umbers needed to track a late and infrequent adverse
utcome.
How you will read these data will be influenced by what
ou want to do with them. I read them to mean that both
MS and DES, with or without dual-antiplatelet therapy,
re subject to potential late thrombosis. I would hasten to
oint out that so can saphenous vein grafts and arterial
ypass conduits. It is important for us to remember that
very tentative step we take to help patients necessarily
nvolves potential risks to harm them.
To paraphrase my late mentor, J. Ward Kennedy, this
roves what I have always said: Caregivers should consider
medically refractory” ischemia as the primary reason to
onsider revascularization, generically (19). Interventionists
nd noninvasive cardiologists should consider the CABG
lternative, including consideration of its morbidity (20).
he importance of optimal medical therapy before and after
ither revascularization strategy is re-emphasized (20). Op-
imal PCI technique, including the appropriate use of
ntravascular ultrasound and adjunctive pharmacology
which continues to improve daily), is also emphasized by
he recognition of late complications (21). Nothing, noth-
ng, nothing—not statins, not angiotensin-receptor block-
rs, not beta-blockers, and most assuredly, neither BMS nor
ES nor bypass grafts—constitutes either a cure for coro-
ary artery disease or is risk free (20,21).
eprints requests and correspondence: Dr. Douglass A. Morri-
on, Interventional Cardiologist, Yakima Heart Center, 406 S
0th Avenue, Yakima, Washington 98902. E-mail: dmorrison1249@
sn.com.
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